c/retatrutide wiki

What this community is for

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

c/retatrutide was created on 6 Sep 2023 and currently has 64,900 members and 130 captured submissions. It sits in the busiest tier of the site, which mostly affects how fast a question gets answered rather than how well.

Rules, and why each exists

Community rules come first, then the six site-wide rules that apply everywhere on GLP Research Hub. Community rules are enforced by the moderators listed at the bottom of this page; site rules are enforced by everyone.

1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
3. Heart-rate and dose-escalation reports need actual measurements, not impressions.

And the site rules, which are short on purpose:

1. Independent community. Nobody here sells anything, and anyone who tries is banned.
2. Not medical advice. Describe what you did; never prescribe to a stranger.
3. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
4. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
5. No contact handles, wallet addresses or tracking numbers — they identify people.
6. Be recognisably decent. Disagree hard, insult nobody.

Terms you will see

Vocabulary that turns up constantly in c/retatrutide. Each links to the topic page, which collects every submission that touches it.

• retatrutide — triple GIP/GLP-1/glucagon receptor agonist, still in development.
• triple agonist — discussed frequently in this community — see the topic page for every submission that touches it.
• glucagon — discussed frequently in this community — see the topic page for every submission that touches it.
• TRIUMPH — discussed frequently in this community — see the topic page for every submission that touches it.
• phase 2 — discussed frequently in this community — see the topic page for every submission that touches it.
• dose escalation — discussed frequently in this community — see the topic page for every submission that touches it.

Start here

The twelve highest-scoring submissions in this community. Not necessarily the most correct — the most agreed-with, which is a different thing, and worth remembering when you read them.

1. 10 months in and dose escalation is still the thing I get wrong — 16k points, 40 comments, 2 years ago
2. unpopular opinion: most of what gets said here about phase 2 is guesswork — 13k points, 33 comments, 1 year ago
3. [Lab] WXT reta — PeptideMeter came back 97.7% against a claimed 97.0% — 9.9k points, 52 comments, 1 year ago
4. [Results] 57 weeks, 25kg, and glucagon was the hard part — 8.5k points, 37 comments, 1 year ago
5. week 19 check-in — 9kg down, early fullness manageable, one thing confusing me — 8.3k points, 41 comments, 2 years ago
6. [Results] 45 weeks on 0.25mg, full numbers, ask me anything boring — 8.3k points, 44 comments, 1 year ago
7. small win: triple agonist stopped being a problem at week 65 — 8k points, 12 comments, 2 years ago
8. triple agonist is the most under-discussed thing on this board — 7.8k points, 38 comments, 1 year ago
9. why does nobody talk about glucagon — 7.8k points, 29 comments, 11 months ago
10. what would you tell week-1 you about glucagon — 7.6k points, 42 comments, 1 year ago
11. stalled for 17 weeks at 2.5mg and I refuse to panic this time — 7.5k points, 23 comments, 2 years ago
12. [Lab] 2th independent test on BCH — 97.8% on a claimed 97.5%, and the trend is the interesting part — 7.5k points, 35 comments, 2 years ago

Asked constantly

• the glucagon arm is why the appetite effect feels different
• reta made me not want food OR water and that is its own problem
• [Question] why is reta purity testing so much more variable between labs
• the dose escalation question that gets asked weekly, answered properly
• TRIUMPH is the most under-discussed thing on this board
• triple agonist: what the trials say vs what this community says
• [Question] is 97.9% actually fine or am I being sold a rounding error
• help me understand triple agonist, I have read the wiki twice
• dose escalation — my 2-week log, condensed into one table
• three years of TRIUMPH threads, summarised so you do not have to read them

If your question is on that list, read the answers there first. If it is not, ask it — that is what the community is for, and "this has been asked" is only a helpful reply when it comes with a link.

Who runs this

Moderation here is done by volunteers who also post as normal members. They are not clinicians, not vendors, and not paid.

• u/reta_and_regret — Went too fast on retatrutide. Learned. Posting the whole embarrassing arc.
• u/trialwatch_theo — I read the supplementary appendix so you do not have to. Pre-registration or it is a hypothesis.
• u/incretin_ivy — GIP/GLP-1 co-agonism is genuinely interesting pharmacology, separate from the weight story.
• u/ledger_mod — c/vendorvetting + c/scamalerts mod. Every claim needs a receipt or it gets a [needs source] flair.